1 / 19

RTOG 9802: the end of the beginning?

RTOG 9802: the end of the beginning? . Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting. Low grade glioma. Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting. What are the issues?. Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting. R9802 SCHEMA.

austin
Download Presentation

RTOG 9802: the end of the beginning?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. RTOG 9802: the end of the beginning? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  2. Low grade glioma Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  3. What are the issues? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  4. R9802 SCHEMA Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  5. Presented at ASCO 2008, published 2012 Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  6. What were the issues? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  7. ASCO 2014: Overall Survival Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  8. Conclusions Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  9. Three trials on adjuvant PCV chemotherapy: the anaplastic OD and LGG trials Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  10. Delayed benefit of chemotherapy Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  11. New WHO grading scheme? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  12. What are the unanswered questions? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  13. What are the unanswered questions? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  14. What are the unanswered questions? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  15. EORTC 22033 on RT vs TMZ in low grade glioma: PFS in relation to 1p status Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  16. Slide 16 Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  17. 2014: the role of chemotherapy established in all diffuse glioma Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  18. Now what? Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

  19. Slide 19 Presented By Martin Van Den Bent at 2014 ASCO Annual Meeting

More Related